GRM2 and Alzheimer disease: Although none of the AMPA, mGlu5 or mGlu7 receptor ligands have so far demonstrated significant AD efficacy in clinical trials, modulation of mGlu2/3 receptors continues to hold promise for the development of safer and more efficacious antidepressants [19].